The efficacy and safety of induction chemoradiotherapy (ICRT) followed by surgery in stage III NSCLC patients (pts) with T3/4-adjacent organ invasion involved(AOI): A single-center retrospective observational study.

M. Nemoto (Kamogawa, Japan), M. Misawa (Kamogawa, Japan), H. Nomori (Kamogawa, Japan), A. Tateishi (Kamogawa, Japan), R. Tsuzuki (Kamogawa, Japan), A. Otsuki (Kamogawa, Japan), K. Nakashima (Kamogawa, Japan), Y. Oyama (Kamogawa, Japan), H. Sugimura (Kamogawa, Japan), K. Shoji (Kamogawa, Japan), M. Aoshima (Kamogawa, Japan)

Source: International Congress 2018 – Lung cancer: personalised medicine

Session: Lung cancer: personalised medicine
Session type: Poster Discussion
Number: 2223

Disease area: Thoracic oncology

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Nemoto (Kamogawa, Japan), M. Misawa (Kamogawa, Japan), H. Nomori (Kamogawa, Japan), A. Tateishi (Kamogawa, Japan), R. Tsuzuki (Kamogawa, Japan), A. Otsuki (Kamogawa, Japan), K. Nakashima (Kamogawa, Japan), Y. Oyama (Kamogawa, Japan), H. Sugimura (Kamogawa, Japan), K. Shoji (Kamogawa, Japan), M. Aoshima (Kamogawa, Japan). The efficacy and safety of induction chemoradiotherapy (ICRT) followed by surgery in stage III NSCLC patients (pts) with T3/4-adjacent organ invasion involved(AOI): A single-center retrospective observational study.. 2223

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Randomized phase II study of adjuvant cisplatin/docetaxel (Cis-Doc) or cisplatin/vinorelbine (Cis-VRB) in patients (pts) with resected stage IB-II NSCLC: interim analysis Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non small cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Multicenter phase II trial of carboplatin (Cb) and gemcitabine (G) followed by concurrent chemoradiation (CRT) in patients with unresectable stage III non-small-cell-lung cancer (NSCLC): Cher@Nos trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
The causes and consequences for dose reduction in NSCLC IIIB patients, a retrospective single center clinical trial. Source: Virtual Congress 2021 – COVID-19 and management of lung cancer Year: 2021
A three-arm phase III randomised trial assessing, in patients with extensive-disease (ED) small-cell lung cancer (SCLC), accelerated chemotherapy with the support of haematological growth factor or of oral antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001
A preliminary comprehensive hormonal evaluation on a prospective group of patients (pts) with advanced lung cancer Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009
A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Early concurrent normo- and hyperfractionated chemoradiotherapy in limited small cell lung cancer (LSCLC): a nonrandomized comparison of 22 consecutive patients Source: Eur Respir J 2001; 18: Suppl. 33, 394s Year: 2001
Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011
Preliminary results of a multicenter randomized phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection Source: Eur Respir J, 56 (5) 2000118; 10.1183/13993003.00118-2020 Year: 2020
A preliminary study comparing pemetrexed/carboplatin (PC) versus docetaxel/carboplatin (DC) as second line therapy in lung cancer patients Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) vs gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003